Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Status:
Recruiting
Trial end date:
2023-12-07
Target enrollment:
Participant gender:
Summary
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of
inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated
low density lipoprotein cholesterol (LDL-C).